Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite, a Gilead Company and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the…
Read More...
Read More...
